Denali Therapeutics Inc. (DNLI) stock plummeted 5.16% intraday on Tuesday.
The decline comes after Oppenheimer analyst Jay Olson lowered the firm's price target on Denali Therapeutics to $42 from $50, while maintaining an Outperform rating. The analyst lowered the probability of success for DNL343 for ALS, citing the company's quarterly results and insights from the CEO at Oppenheimer's healthcare conference.
Despite the lowered price target, Oppenheimer remains optimistic about Denali's multiple opportunities ahead, including the anticipated filing for DNL310 in Hunter syndrome and the expansion of the company's ETV platform to address more common diseases.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。